NEW YORK, Oct. 1 - Symyx Technologies and Prolinx have signed a non-exclusive license agreement under which Prolinx will commercialize products that contain a novel polymer developed by Symyx, the company said on Monday.
Terms of the agreement, which is Symyx’s first in proteomics, call for Prolinx to use the Symyx polymer in combination with its own Versalinx chemical affinity tools to support its proteomic product pipeline, Symyx said in a statement. If successful, Prolinx would create the first commercial product to employ Symyx technology, the statement added.
According to Santa Clara, Calif.-based Symyx, Prolinx will use its polymer as part of its effort to launch substrates and protein arrays before the end of the year.
Although financial details of the deal were not disclosed, Symyx said it expects to receive royalties from the sale of these products in early 2002.
Prolinx, of Bothell, Wash., hopes to incorporate the three-dimensional structure of the Symyx polymer, which provides support for protein capture and expression analysis, to gain an advantage in its protein immobilization efforts. Privately held Prolinx, for whom a $16.8 million financing round in July helped make this deal possible, will initially commercialize these technologies in substrates for protein capture, and will later expand to include custom and catalog protein arrays, Symyx said.
"This alliance came together quickly, and the strong combination of the Prolinx chemistry with our polymer should enable a rollout this year, making this the first commercial product to incorporate one of our materials," said Steve Goldby, chairman and CEO of Symyx. "We are very pleased to work with Prolinx as our initial partner in proteomics, and anticipate working with other companies as well to commercialize our materials in a broad range of products in this fast moving field."